Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Inflammatory Bowel Diseases | 14 | 2021 | 3209 | 0.99 | Why? |
| Ileitis | 2 | 2018 | 21 | 0.93 | Why? |
| Colitis, Ulcerative | 3 | 2020 | 1037 | 0.85 | Why? |
| Crohn Disease | 3 | 2018 | 959 | 0.84 | Why? |
| Biological Therapy | 2 | 2021 | 456 | 0.79 | Why? |
| Elasticity Imaging Techniques | 2 | 2018 | 194 | 0.74 | Why? |
| Pouchitis | 1 | 2017 | 20 | 0.71 | Why? |
| Proctocolectomy, Restorative | 1 | 2017 | 51 | 0.69 | Why? |
| Cholangitis, Sclerosing | 1 | 2017 | 106 | 0.62 | Why? |
| Reoperation | 1 | 2018 | 544 | 0.59 | Why? |
| Intestines | 2 | 2018 | 817 | 0.55 | Why? |
| Digestive System Surgical Procedures | 1 | 2018 | 677 | 0.44 | Why? |
| T-Box Domain Proteins | 2 | 2019 | 62 | 0.39 | Why? |
| Th1 Cells | 4 | 2019 | 1228 | 0.38 | Why? |
| T-Lymphocytes, Regulatory | 3 | 2019 | 698 | 0.36 | Why? |
| Colitis | 3 | 2021 | 266 | 0.34 | Why? |
| Intestinal Mucosa | 4 | 2019 | 1046 | 0.30 | Why? |
| Infliximab | 2 | 2018 | 502 | 0.26 | Why? |
| Th17 Cells | 2 | 2018 | 657 | 0.24 | Why? |
| Mesalamine | 1 | 2020 | 89 | 0.20 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.20 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2018 | 2483 | 0.19 | Why? |
| Professional Practice Gaps | 1 | 2018 | 41 | 0.18 | Why? |
| Mesentery | 1 | 2018 | 43 | 0.18 | Why? |
| Patient Care Management | 2 | 2020 | 1514 | 0.17 | Why? |
| Biological Factors | 1 | 2021 | 276 | 0.17 | Why? |
| Interleukin-13 | 1 | 2019 | 204 | 0.17 | Why? |
| Remission Induction | 2 | 2018 | 950 | 0.17 | Why? |
| JC Virus | 1 | 2017 | 39 | 0.17 | Why? |
| Adalimumab | 2 | 2018 | 389 | 0.17 | Why? |
| Fibrosis | 2 | 2018 | 800 | 0.16 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 9335 | 0.16 | Why? |
| Receptors, CCR5 | 1 | 2018 | 186 | 0.16 | Why? |
| Staff Development | 1 | 2018 | 222 | 0.14 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| Italy | 10 | 2021 | 38444 | 0.14 | Why? |
| Graft vs Host Disease | 1 | 2018 | 501 | 0.14 | Why? |
| Professional Practice | 1 | 2018 | 322 | 0.14 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.13 | Why? |
| Intestinal Diseases | 1 | 2017 | 231 | 0.13 | Why? |
| Wound Healing | 1 | 2018 | 424 | 0.13 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.13 | Why? |
| Hospital Units | 1 | 2020 | 1017 | 0.13 | Why? |
| Gastrointestinal Agents | 1 | 2017 | 393 | 0.13 | Why? |
| Ageusia | 1 | 2021 | 918 | 0.13 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.12 | Why? |
| Organ Culture Techniques | 1 | 2012 | 119 | 0.12 | Why? |
| Dermatologic Agents | 1 | 2018 | 489 | 0.11 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.11 | Why? |
| Lactobacillus | 1 | 2012 | 92 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.11 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.10 | Why? |
| Trust | 1 | 2020 | 1487 | 0.10 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.10 | Why? |
| Gene Expression Regulation | 2 | 2019 | 4020 | 0.10 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.09 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.09 | Why? |
| Videoconferencing | 1 | 2020 | 2081 | 0.09 | Why? |
| Attitude to Health | 1 | 2020 | 2002 | 0.08 | Why? |
| Blood Donors | 1 | 2021 | 2956 | 0.08 | Why? |
| Adult | 12 | 2021 | 244371 | 0.08 | Why? |
| Germany | 1 | 2021 | 9196 | 0.07 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.07 | Why? |
| Female | 16 | 2021 | 380317 | 0.07 | Why? |
| Cytokines | 3 | 2018 | 15010 | 0.07 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
| Male | 14 | 2021 | 367725 | 0.07 | Why? |
| Treatment Outcome | 4 | 2018 | 51732 | 0.07 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.07 | Why? |
| Probiotics | 1 | 2012 | 694 | 0.07 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.07 | Why? |
| Fever | 1 | 2021 | 7795 | 0.07 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.06 | Why? |
| Humans | 25 | 2021 | 930598 | 0.06 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.06 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Multiple Sclerosis | 1 | 2017 | 2600 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Antigens, Viral | 1 | 2017 | 6298 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Mice | 4 | 2019 | 21357 | 0.05 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.05 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.05 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.05 | Why? |
| Granzymes | 1 | 2018 | 197 | 0.04 | Why? |
| Confidence Intervals | 1 | 2021 | 744 | 0.04 | Why? |
| Homeodomain Proteins | 1 | 2018 | 93 | 0.04 | Why? |
| Clone Cells | 1 | 2018 | 312 | 0.04 | Why? |
| Aminosalicylic Acid | 1 | 2017 | 8 | 0.04 | Why? |
| Cell Lineage | 1 | 2018 | 241 | 0.04 | Why? |
| Permeability | 1 | 2018 | 238 | 0.04 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.04 | Why? |
| Tight Junctions | 1 | 2018 | 179 | 0.04 | Why? |
| Natural Killer T-Cells | 1 | 2019 | 191 | 0.04 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.04 | Why? |
| Mercaptopurine | 1 | 2017 | 68 | 0.04 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.04 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.04 | Why? |
| Natalizumab | 1 | 2017 | 144 | 0.04 | Why? |
| Fingolimod Hydrochloride | 1 | 2017 | 217 | 0.04 | Why? |
| Th2 Cells | 1 | 2019 | 680 | 0.04 | Why? |
| Streptococcus agalactiae | 1 | 1995 | 194 | 0.03 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.03 | Why? |
| Colonic Neoplasms | 1 | 2018 | 295 | 0.03 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.03 | Why? |
| Regression Analysis | 1 | 2021 | 2484 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Methotrexate | 1 | 2017 | 471 | 0.03 | Why? |
| Surveys and Questionnaires | 4 | 2020 | 43792 | 0.03 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.03 | Why? |
| Animals | 5 | 2019 | 78931 | 0.03 | Why? |
| Streptococcal Infections | 1 | 1995 | 255 | 0.03 | Why? |
| Salmonella | 1 | 2012 | 58 | 0.03 | Why? |
| Interleukin-10 | 1 | 2018 | 1409 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Aftercare | 1 | 2020 | 1637 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.03 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.03 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.02 | Why? |
| Gastroenterology | 1 | 2018 | 1352 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Immunologic Memory | 1 | 2018 | 3362 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| Aged | 6 | 2021 | 215776 | 0.02 | Why? |
| Lymphocytes | 1 | 2019 | 3056 | 0.02 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.02 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.02 | Why? |
| Cholelithiasis | 1 | 1965 | 47 | 0.02 | Why? |
| Immunohistochemistry | 1 | 2012 | 2275 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Intestinal Obstruction | 1 | 1965 | 197 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.01 | Why? |
| Immunity, Innate | 1 | 2019 | 6570 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.01 | Why? |
| Quality of Life | 1 | 2020 | 9820 | 0.01 | Why? |
| Dietary Supplements | 1 | 2012 | 2251 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Anti-Bacterial Agents | 2 | 2017 | 10083 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Pregnancy | 2 | 2017 | 23879 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Obstetric Labor Complications | 1 | 1995 | 119 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 1995 | 11559 | 0.01 | Why? |
Caprioli's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(179)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(148)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_